Skip to content
Open access

Clinical utility of circulating tumor-derived endothelial cells in lung cancer detection and prognosis prediction

Sep 2026 · Oncology Letters · Vol 32 · 0 citations · 35 references
Medicine

TL;DR

It is suggested that CTEC may serve as reliable supplementary biomarkers for lung cancer screening, disease monitoring and prognosis prediction.

Abstract

Circulating tumor-derived endothelial cells (CTEC) have emerged as promising biomarkers reflecting tumor angiogenesis, disease progression and therapeutic response, although their clinical relevance in lung cancer remains underexplored. A total of 74 patients with lung cancer were enrolled in the present study, and both preoperative and postoperative peripheral blood samples were collected. A total of 20 healthy individuals were included as controls. CTEC (CD31+ aneuploid cells) and circulating tumor cells (CTC; CD31− aneuploid cells) were simultaneously detected using an improved subtraction enrichment and immunostaining-fluorescence in situ hybridization technique. The overall positive detection rates of CTC and CTEC were 68.75 and 81.25%, respectively. CTEC accounted for a greater proportion of circulating rare cells in patients with lung cancer, and CTEC counts were significantly elevated in those with lymph node metastasis compared with CTC. Receiver operating characteristic curve analysis demonstrated that CTEC [area under the curve (AUC), 0.855] performed better than CTC (AUC, 0.673) in distinguishing patients with lung cancer from healthy controls. Furthermore, a preoperative CTEC count ≥1 was identified as an independent risk factor for shorter progression-free survival. These findings suggested that CTEC may serve as reliable supplementary biomarkers for lung cancer screening, disease monitoring and prognosis prediction.

Read PDF

Similar papers

Open access Sep 2026

The phenotypic heterogeneity of tumor-derived cells in the bloodstream of pancreatic cancer patients

These findings provide a comprehensive characterization of CTCs and CTACs in PC using a multiplex biomarker panel associated with calcium signaling and immune checkpoint pathways, highlighting the pronounced heterogeneity and potential clinical relevance of these circulating cell populations.

Chrysoula Tagari, Karolina Mangani, Michael Gogolides et al. · 0 citations
Open access Sep 2026

The circulating tumor microenvironment in small-cell lung cancer: Vimentin-positive circulating tumor endothelial cells as drivers of metastasis and poor prognosis in a large cohort study.

Investigation of the critical role of CD31+ aneuploid circulating tumor endothelial cells expressing vimentin in promoting SCLC metastasis concluded that Vim+ CTECs serve as a key driver of tumor metastasis in SCLC.

Ying Wang, Fei Qi, Ming-Hang Zhang et al. · 0 citations
Open access Sep 2026

Correlation between circulating tumor cell levels and tumor response in patients with advanced hepatocellular carcinoma undergoing immunotherapy and molecular targeted therapy

Circulating tumor cells (CTCs) are closely associated with the progression of hepatocellular carcinoma (HCC). However, the clinical value of CTC detection in patients receiving systemic therapy for advanced HCC remains to be fully elucidated. A total of 125 patients with advanced HCC who underwent systemic therapy were...

Jiang-Min Zhou, Hui-Fang Xiong, Hong-Hao Zhou et al. · 0 citations
Aug 2026

Low Stromal CD11c Expression Indicates a Poor Prognosis in Rectal Cancer Patients.

It is suggested that stromal CD11c expression captures the distinct immunological characteristics of rectal cancer compared to colon cancer, and could serve as a prognostic marker for rectal cancer patients.

R-M. Penttinen, T. Kaprio, J. Hagström et al. · 0 citations
Open access Sep 2026

Folate receptor-positive circulating tumor cells as a potential biomarker for breast cancer diagnosis

Objectives: This study investigated the potential of folate receptor-positive circulating tumor cells (FR+CTCs) as a non-invasive biomarker for breast cancer diagnosis and clinical stratification. Materials and Methods: Between January 2024 and October 2024, 179 breast cancer patients and 38 patients with benign breast...

Juan Li, Jing Fu, Dan-Dan Zhang et al. · 0 citations
Open access Sep 2026

Immune-Excluded CD4⁺ and CD8⁺ T-Cell Depletion Predicts Early Recurrence in Hepatocellular Carcinoma with Microvascular Invasion

Background: Early recurrence within six months after resection continues to pose a major clinical challenge in hepatocellular carcinoma (HCC) patients, occurring in approximately 31.9% of patients. This study aims to investigate whether reduced immune cell infiltration across intratumoral and peritumoral compartments i...

Lianda Siregar, R. Gani, T. Lalisang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.